Restaurant menu – how do you read?

When you sit down to read a restaurant menu, do you read it like a book? Or do your eyes flit from place to place to find the most enticing dish?

A new study by SF State researcher Sybil Yang, assistant professor of hospitality and tourism management, suggests that on average diners read menus sequentially like a book, and that their gaze doesn’t linger noticeably longer over any particular location on the menu.

continue reading

Cancer :: GSK & Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology

GlaxoSmithKline (GSK) and Synta Pharmaceuticals Corp. announced the execution of a global collaboration agreement for the joint development and commercialisation of STA-4783, a first-in-class, small-molecule, oxidative stress inducer that is entering Phase 3 clinical development for the treatment of metastatic melanoma.

Medicine :: Shire supports Canada’s Access to Medicines Regime

Shire BioChem Inc. announced that it is pleased to support Canada?s Access to Medicines Regime to enable a Canadian company (Apotex) to manufacture in Canada a generic fixed dose triple combination antiretroviral medicine that contains a drug (3TC?) over which Shire BioChem Inc. holds patent rights in Canada.

HIV :: AHF Welcomes FDA Approval of Pfizer?s Selzentry AIDS Drug

On the heels of the fourth International AIDS Society?s Conference on HIV Pathogenesis, Treatment and Prevention, which took place in Sydney in late July, AIDS Healthcare Foundation (AHF) welcomed yesterday?s news that the FDA has approved Pfizer Inc.?s new AIDS salvage therapy, Selzentry (maraviroc), a different class of new antiretroviral AIDS drug which had been discussed and presented at the IAS conference.

HIV :: GSK gives consent for generic version of HIV/AIDS medicine for use in Rwanda

As part of its broad commitment to improving access to medicines, GlaxoSmithKline announced it has given consent through Canada?s Access to Medicines Regime to enable a Canadian company (Apotex) to manufacture a generic fixed dose combination (FDC) antiretroviral (ARV), containing two molecules over which GSK has patent rights (zidovudine and lamivudine) for the treatment of HIV/AIDS in Rwanda.